These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38428307)

  • 41. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
    Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
    Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
    Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
    Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
    Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
    FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
    Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
    Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chronic sucralose consumption inhibits farnesoid X receptor signaling and perturbs lipid and cholesterol homeostasis in the mouse livers, potentially by altering gut microbiota functions.
    Chi L; YifeiYang ; Bian X; Gao B; Tu P; Ru H; Lu K
    Sci Total Environ; 2024 Apr; 919():169603. PubMed ID: 38272087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice.
    Jiang J; Ma Y; Liu Y; Lu D; Gao X; Krausz KW; Desai D; Amin SG; Patterson AD; Gonzalez FJ; Xie C
    Hepatol Commun; 2022 Dec; 6(12):3363-3378. PubMed ID: 36196594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
    Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
    Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liver Steatosis and Steatohepatitis Alter Bile Acid Receptors in Brain and Induce Neuroinflammation: A Contribution of Circulating Bile Acids and Blood-Brain Barrier.
    Fiaschini N; Mancuso M; Tanori M; Colantoni E; Vitali R; Diretto G; Lorenzo Rebenaque L; Stronati L; Negroni A
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathway.
    Yang F; Lv XT; Lin XL; Wang RH; Wang SM; Wang GE
    Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1961-1971. PubMed ID: 37997375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
    Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
    J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.
    Duparc T; Plovier H; Marrachelli VG; Van Hul M; Essaghir A; Ståhlman M; Matamoros S; Geurts L; Pardo-Tendero MM; Druart C; Delzenne NM; Demoulin JB; van der Merwe SW; van Pelt J; Bäckhed F; Monleon D; Everard A; Cani PD
    Gut; 2017 Apr; 66(4):620-632. PubMed ID: 27196572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation.
    Shu X; Li M; Cao Y; Li C; Zhou W; Ji G; Zhang L
    Front Pharmacol; 2021; 12():750826. PubMed ID: 34603061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.